EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
First Claim
Patent Images
1. An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising:
- (a) pregelatinized starch; and
(b) an anionic polymer.
0 Assignments
0 Petitions
Accused Products
Abstract
An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix, the matrix comprising at least two water swelling polymers, wherein one of the polymers is pregelatinized starch, and wherein another one of the polymers is an anionic polymer.
-
Citations
26 Claims
-
1. An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising:
-
(a) pregelatinized starch; and (b) an anionic polymer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
-
-
12. An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising:
-
(a) at least pregelatinized starch as water swelling polymer and optionally excipients, the resulting tablet providing a pH-independent in vitro release characteristic in the range from pH 1 to 7.5, or (b) at least pregelatinized starch as water swelling polymer, a water swelling anionic polymer, and optionally excipients, the resulting tablet providing a pH-dependent release characteristic with a faster release characteristic in the range of pH<
4.5, and a slower and further on pH-independent release characteristic in the range from pH 4.5 to 7.5. - View Dependent Claims (14, 15)
-
Specification